Trial Profile
Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2010
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Sep 2010 New trial record
- 20 Sep 2010 Results reported at the 46th annual meeting of the European Association for the Study of Diabetes